Biogen BIIB will report second-quarter 2025 results on July 31, before market open. In the last reported quarter, the company's earnings missed expectation by 7.4%. The Zacks Consensus Estimate for ...

EMA committee recommends marketing approval for Biogen’s Zurzuvae to treat women with postpartum depression: Cambridge, Massachusetts Monday, July 28, 2025, 17:00 Hrs [IST] Biog ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products for Human Use (CHMP) has ...

Biogen (NASDAQ:BIIB), and Ionis Pharmaceuticals (NASDAQ:IONS) announced that the European Medicines Agency (EMA) has given positive endorsements for their products. The EMA's Committee for Medicinal ...

Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real ...

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Biogen, with a price target of $224.00. The company’s shares closed yesterday at $130.13. Do ...

Two weeks after Supernus unveiled the Sage Therapeutics acquisition, all 338 employees from the struggling biotech are being laid off.

Without the contingency offer, the deal value comes up to $561 million. In January, Sage rejected a $469 million bid from Biogen, which co-developed Zurzuvae. The transaction with Supernus is expected ...

According to the complaint, during that time period Sage and certain of the company's senior executive officers concealed from investors adverse information and substantial risks associated with ...

Biogen and City Therapeutics are collaborating to develop select RNAi therapies in a $46 million partnership. City Therapeutics, a private biopharmaceutical company, will offer its RNAi ...